Arai MA et al. |
Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana. |
2008 |
Bioorg. Med. Chem. |
pmid:18842418
|
Lewis Phillips GD et al. |
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. |
2008 |
Cancer Res. |
pmid:19010901
|
Ishitsuka K et al. |
Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. |
2008 |
Br. J. Haematol. |
pmid:18279455
|
Taft F et al. |
Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant. |
2008 |
Chembiochem |
pmid:18381586
|
Polson AG et al. |
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. |
2009 |
Cancer Res. |
pmid:19258515
|
Taft F et al. |
Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. |
2009 |
J. Am. Chem. Soc. |
pmid:19292483
|
Wang L et al. |
Formal total synthesis of N-methylmaysenine. |
2009 |
Org. Lett. |
pmid:19296671
|
Ikeda H et al. |
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. |
2009 |
Clin. Cancer Res. |
pmid:19509164
|
Al-Katib AM et al. |
Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. |
2009 |
Clin. Cancer Res. |
pmid:19509168
|
Tang R et al. |
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. |
2009 |
BMC Cancer |
pmid:19549303
|
Ng D et al. |
Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum. |
2009 |
J. Ind. Microbiol. Biotechnol. |
pmid:19609582
|
Zheng B et al. |
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. |
2009 |
Mol. Cancer Ther. |
pmid:19808977
|
Haeuw JF et al. |
[Immunoconjugates, drug-armed antibodies to fight against cancer]. |
2009 |
Med Sci (Paris) |
pmid:20035677
|
Lutz RJ and Whiteman KR |
Antibody-maytansinoid conjugates for the treatment of myeloma. |
2009 Nov-Dec |
MAbs |
pmid:20068397
|
Higa GM et al. |
Biological considerations and clinical applications of new HER2-targeted agents. |
2010 |
Expert Rev Anticancer Ther |
pmid:20836684
|
Erickson HK et al. |
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. |
2010 |
Bioconjug. Chem. |
pmid:19891424
|
Wang HH et al. |
Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. |
2010 |
J. Alzheimers Dis. |
pmid:20413892
|
Yao Y et al. |
Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography. |
2010 |
J Sep Sci |
pmid:20235129
|
Wei GZ et al. |
A new antitumour ansamitocin from Actinosynnema pretiosum. |
2010 |
Nat. Prod. Res. |
pmid:20582809
|
Kovtun YV et al. |
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. |
2010 |
Cancer Res. |
pmid:20197459
|